These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22922766)

  • 1. Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.
    Hartikka J; Bozoukova V; Morrow J; Rusalov D; Shlapobersky M; Wei Q; Boutsaboualoy S; Ye M; Wloch MK; Doukas J; Sullivan S; Rolland A; Smith LR
    Hum Vaccin Immunother; 2012 Nov; 8(11):1595-606. PubMed ID: 22922766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens.
    Hartikka J; Bozoukova V; Ferrari M; Sukhu L; Enas J; Sawdey M; Wloch MK; Tonsky K; Norman J; Manthorpe M; Wheeler CJ
    Vaccine; 2001 Feb; 19(15-16):1911-23. PubMed ID: 11228361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA.
    Vilalta A; Shlapobersky M; Wei Q; Planchon R; Rolland A; Sullivan S
    Vaccine; 2009 Dec; 27(52):7409-17. PubMed ID: 19735757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection.
    Shlapobersky M; Marshak JO; Dong L; Huang ML; Wei Q; Chu A; Rolland A; Sullivan S; Koelle DM
    J Gen Virol; 2012 Jun; 93(Pt 6):1305-1315. PubMed ID: 22398318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.
    McVoy MA; Lee R; Saccoccio FM; Hartikka J; Smith LR; Mahajan R; Wang JB; Cui X; Adler SP
    Vaccine; 2015 Dec; 33(51):7328-7336. PubMed ID: 26597035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration.
    Vilalta A; Mahajan RK; Hartikka J; Rusalov D; Martin T; Bozoukova V; Leamy V; Hall K; Lalor P; Rolland A; Kaslow DC
    Hum Gene Ther; 2005 Oct; 16(10):1143-50. PubMed ID: 16218775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.
    Doukas J; Morrow J; Bellinger D; Hilgert T; Martin T; Jones D; Mahajan R; Rusalov D; Sullivan S; Rolland A
    Vaccine; 2011 Jul; 29(33):5443-52. PubMed ID: 21641955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration.
    Gramzinski RA; Millan CL; Obaldia N; Hoffman SL; Davis HL
    Mol Med; 1998 Feb; 4(2):109-18. PubMed ID: 9508788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.
    Lin WH; Vilalta A; Adams RJ; Rolland A; Sullivan SM; Griffin DE
    J Virol; 2013 Jun; 87(12):6560-8. PubMed ID: 23552419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved tuberculosis DNA vaccines by formulation in cationic lipids.
    D'Souza S; Rosseels V; Denis O; Tanghe A; De Smet N; Jurion F; Palfliet K; Castiglioni N; Vanonckelen A; Wheeler C; Huygen K
    Infect Immun; 2002 Jul; 70(7):3681-8. PubMed ID: 12065510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device.
    Cui Z; Baizer L; Mumper RJ
    J Biotechnol; 2003 Apr; 102(2):105-15. PubMed ID: 12697387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.
    Raviprakash K; Luke T; Doukas J; Danko J; Porter K; Burgess T; Kochel T
    Hum Vaccin Immunother; 2012 Dec; 8(12):1764-8. PubMed ID: 23032166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
    Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
    Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases.
    Selinsky C; Luke C; Wloch M; Geall A; Hermanson G; Kaslow D; Evans T
    Hum Vaccin; 2005; 1(1):16-23. PubMed ID: 17038834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.
    McCluskie MJ; Brazolot Millan CL; Gramzinski RA; Robinson HL; Santoro JC; Fuller JT; Widera G; Haynes JR; Purcell RH; Davis HL
    Mol Med; 1999 May; 5(5):287-300. PubMed ID: 10390545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
    Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.
    Sedegah M; Rogers WO; Belmonte A; Belmonte M; Banania G; Patterson N; Ferrari M; Kaslow DC; Carucci DJ; Richie TL; Doolan DL
    Vaccine; 2006 Mar; 24(11):1921-7. PubMed ID: 16298024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes.
    Epstein JE; Gorak EJ; Charoenvit Y; Wang R; Freydberg N; Osinowo O; Richie TL; Stoltz EL; Trespalacios F; Nerges J; Ng J; Fallarme-Majam V; Abot E; Goh L; Parker S; Kumar S; Hedstrom RC; Norman J; Stout R; Hoffman SL
    Hum Gene Ther; 2002 Sep; 13(13):1551-60. PubMed ID: 12228010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83.
    Schleiss MR; Bourne N; Jensen NJ; Bravo F; Bernstein DI
    Viral Immunol; 2000; 13(2):155-67. PubMed ID: 10892996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery.
    Williams M; Ewing D; Blevins M; Sun P; Sundaram AK; Raviprakash KS; Porter KR; Sanders JW
    Vaccine; 2019 Jul; 37(32):4444-4453. PubMed ID: 31279565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.